Search research articles
Contact Us
Filters
Showing results (31-40 of 68) with videos related to
Page
of 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2014
Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer
V K Morris, F A San Lucas, M J Overman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2020
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
V Subbiah, T Shen, S S Terzyan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
R Kurzrock, D W Bowles, H Kang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 15, 2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
C Liedtke, K Broglio, S Moulder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2000
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas
F Meric, M Milas, K K Hunt, et al.
ESMO Open
|
November 12, 2025
Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations
S A Piha-Paul, C Tseng, H T Tran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2013
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
M M Kim, P Allen, A M Gonzalez-Angulo, et al.
ESMO Open
|
June 3, 2025
Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET
A Ronaghy, E Crimini, V R Holla, et al.
ESMO Open
|
February 5, 2025
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
S A Piha-Paul, C Tseng, H T Tran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2014
Which threshold for ER positivity? a retrospective study based on 9639 patients
M Yi, L Huo, K B Koenig, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 68) with videos related to
Sort By:
Page
of 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2014
Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer
V K Morris, F A San Lucas, M J Overman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2020
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
V Subbiah, T Shen, S S Terzyan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
R Kurzrock, D W Bowles, H Kang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 15, 2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
C Liedtke, K Broglio, S Moulder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2000
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas
F Meric, M Milas, K K Hunt, et al.
ESMO Open
|
November 12, 2025
Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations
S A Piha-Paul, C Tseng, H T Tran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2013
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
M M Kim, P Allen, A M Gonzalez-Angulo, et al.
ESMO Open
|
June 3, 2025
Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET
A Ronaghy, E Crimini, V R Holla, et al.
ESMO Open
|
February 5, 2025
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
S A Piha-Paul, C Tseng, H T Tran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2014
Which threshold for ER positivity? a retrospective study based on 9639 patients
M Yi, L Huo, K B Koenig, et al.
Page
of 7